Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
---|---|---|---|---|---|
10.09. | Oppenheimer raises Tyra Biosciences stock price target to $36 on market potential | 3 | Investing.com | ||
22.08. | Tyra Biosciences, Inc. - 8-K, Current Report | - | SEC Filings | ||
21.08. | Achondroplasie-Studie: Tyra Biosciences behandelt erstes Kind mit Dabogratinib | 4 | Investing.com Deutsch | ||
21.08. | Tyra Biosciences doses first child in achondroplasia treatment trial | 1 | Investing.com | ||
21.08. | Tyra Biosciences Announces First Child Dosed in BEACH301, its Phase 2 Study for Dabogratinib (TYRA-300) in Pediatric Achondroplasia | 93 | PR Newswire | -Dabogratinib is the only oral FGFR3-selective inhibitor in clinical development for achondroplasia-
-Initial results from safety sentinel cohort expected in 2H... ► Artikel lesen | |
14.08. | Tyra Biosciences, Inc. - 8-K, Current Report | 3 | SEC Filings | ||
14.08. | Tyra Biosciences Reports Second Quarter 2025 Financial Results and Highlights | 564 | PR Newswire | - Dosed first patient in SURF302 for intermediate risk non-muscle invasive bladder cancer (IR NMIBC) -
- Cash, cash equivalents, and marketable securities of $296.3... ► Artikel lesen | |
30.06. | Tyra Biosciences beginnt mit Dosierung in Phase-2-Studie für TYRA-300 bei Blasenkrebs | 1 | Investing.com Deutsch | ||
TYRA BIOSCIENCES Aktie jetzt für 0€ handeln | |||||
30.06. | Tyra Biosciences, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
30.06. | Tyra Biosciences Doses First Patient in Phase 2 Study of TYRA-300 in Low-Grade Intermediate Risk Non-Muscle Invasive Bladder Cancer (SURF302) | 242 | PR Newswire | -TYRA-300 is the only orally administered investigational agent in clinical development for IR NMIBC-
-Initial 3-month complete response (CR) data expected to be... ► Artikel lesen | |
29.05. | Tyra Biosciences, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
21.05. | Piper Sandler raises Tyra Biosciences stock target to $33 | 1 | Investing.com | ||
08.05. | Tyra Biosciences GAAP EPS of -$0.47 | 1 | Seeking Alpha | ||
08.05. | Tyra Biosciences files $500M mixed securities shelf | 4 | Seeking Alpha | ||
08.05. | Tyra Biosciences, Inc. - 8-K, Current Report | - | SEC Filings | ||
08.05. | Tyra Biosciences Reports First Quarter 2025 Financial Results and Highlights | 327 | PR Newswire | - BEACH301 study of TYRA-300 for Pediatric Achondroplasia (ACH) Open for Enrollment -
- Initiated patient dosing in SURF431 study of TYRA-430 for hepatocellular... ► Artikel lesen | |
31.03. | H.C. Wainwright maintains $30 target on Tyra Biosciences stock | 1 | Investing.com | ||
27.03. | Tyra Biosciences GAAP EPS of -$0.43 | 1 | Seeking Alpha | ||
27.03. | Tyra Biosciences Reports Fourth Quarter and Full Year 2024 Financial Results and Highlights | 219 | PR Newswire | - Three INDs cleared by US FDA for TYRA's proprietary precision small molecules -
- TYRA-300 to be evaluated in three Phase 2 studies: SURF302 for Intermediate Risk... ► Artikel lesen | |
27.03. | Tyra Biosciences, Inc. - 8-K, Current Report | 2 | SEC Filings |
Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
---|---|---|---|---|---|
SUMMIT THERAPEUTICS | 18,090 | 0,00 % | Summit Therapeutics stock rating reiterated at Buy by H.C. Wainwright | ||
MINERALYS THERAPEUTICS | 37,290 | 0,00 % | Mineralys Therapeutics, Inc.: Mineralys Therapeutics Announces Late-Breaking Presentation of Data from the Launch-HTN Pivotal Trial of Lorundrostat in Uncontrolled or Resistant Hypertension at 34th European Meeting on Hypertension ... | - Largest hypertension trial of an aldosterone synthase inhibitor to date demonstrated the efficacy of lorundrostat in over 1,000 participants with uncontrolled or resistant hypertension in a real-world... ► Artikel lesen | |
CG ONCOLOGY | 37,510 | 0,00 % | Hedge Fund and Insider Trading News: Ray Dalio, Warren Buffett, Bill Ackman, Dan Loeb, Arrowpoint Investment Partners, CG Oncology Inc (CGON), Tesla Inc (TSLA), and More | ||
SCISPARC | 4,365 | 0,00 % | Morning Market Movers: SciSparc, HIND, SQFT, FGNX See Big Swings | BEIJING (dpa-AFX) - At 7:55 a.m. ET on Wednesday, premarket trading is seeing notable activity in several stocks, with early price movements signaling potential opportunities before the opening... ► Artikel lesen | |
LENZ THERAPEUTICS | 42,230 | 0,00 % | LENZ Therapeutics, Inc.: LENZ Therapeutics and Lotus Pharmaceutical Announce Exclusive License and Commercialization Agreement for LNZ100 in the Republic of Korea and Southeast Asia | SAN DIEGO and TAIPEI, Taiwan, May 09, 2025 (GLOBE NEWSWIRE) -- LENZ Therapeutics, Inc. (Nasdaq: LENZ) and Lotus Pharmaceutical Co., Ltd. ("Lotus", TWSW Stock Code: 1795) today announced an exclusive... ► Artikel lesen | |
EVOTEC | 6,260 | +0,74 % | EQS-NVR: Evotec SE: Veröffentlichung der Gesamtzahl der Stimmrechte nach § 41 WpHG mit dem Ziel der europaweiten Verbreitung | EQS Gesamtstimmrechtsmitteilung: Evotec SE
/ Veröffentlichung der Gesamtzahl der Stimmrechte
Evotec SE: Veröffentlichung der Gesamtzahl der Stimmrechte nach § 41 WpHG mit dem... ► Artikel lesen | |
PRAXIS PRECISION MEDICINES | 44,030 | 0,00 % | Praxis Precision Medicines: Piper Sandler bestätigt "Overweight" nach positiven Studiendaten | ||
JANUX THERAPEUTICS | 23,460 | 0,00 % | Janux Therapeutics: Günstige Gelegenheit | Janux Therapeutics hat mit seiner innovativen Plattformtechnologie im letzten Jahr das Interesse vieler Investoren geweckt - nicht zuletzt aufgrund von Übernahmegerüchten. Doch unabhängig von einem... ► Artikel lesen | |
BEAM THERAPEUTICS | 22,470 | 0,00 % | Fortschritte in der Pipeline: H.C. Wainwright bestätigt "Buy"-Rating für Beam Therapeutics | ||
PHATHOM PHARMACEUTICALS | 11,000 | 0,00 % | Phathom Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | FLORHAM PARK, N.J., June 23, 2025 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal... ► Artikel lesen | |
KINIKSA PHARMACEUTICALS | 35,430 | 0,00 % | Kiniksa Pharmaceuticals International, Plc: Kiniksa Pharmaceuticals Reports Second Quarter 2025 Financial Results and Recent Portfolio Execution | - ARCALYST® (rilonacept) Q2 2025 net product revenue of $156.8 million, representing 52% year-over-year growth -- ARCALYST 2025 expected net product revenue increased to $625 - $640 million -- KPL-387... ► Artikel lesen | |
AVIDITY BIOSCIENCES | 40,060 | 0,00 % | Roth/MKM initiates Avidity Biosciences stock with Buy rating on platform potential | ||
RECURSION PHARMACEUTICALS | 4,720 | 0,00 % | What Analysts Are Saying About Recursion Pharmaceuticals Stock | ||
TOURMALINE BIO | 47,695 | 0,00 % | BMO Capital downgrades Tourmaline Bio stock rating following Novartis acquisition news | ||
STRUCTURE THERAPEUTICS | 21,620 | 0,00 % | JMP bestätigt Rating für Structure Therapeutics nach positiven Sicherheitsdaten |